Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20964691 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL27829814 | 0.83 | PHGDH (0.51) | PHGDHSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL14735155 | 0.81 | PHGDH (0.50) | PHGDHSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL18362064 | 0.80 | PHGDH (0.52) | PHGDHSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL3075186 | 0.80 | CNR2 (0.47) | PHGDHSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL21393062 | 0.78 | KMT2A (0.54) | PHGDHSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL20964676 | 0.77 | PANK3 (0.52) | CNR2 | |
| SCHEMBL20348529 | 0.77 | PHGDH (0.49) | PHGDHSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL2366192 | 0.76 | MEN1 (0.55) | PHGDHSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL31381249 | 0.73 | NOTUM (0.52) | SMN1; SMN2LMNAKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190127361-A1 | Therapeutic Compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127361-A1 | Therapeutic Compounds | SDHA, SLC10A1, SERPINC1 | PHGDH 1177/4885SMN1; SMN2 263/4885LMNA 1413/4885 |
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | SERPINC1, F12, RPL35 | PHGDH 2458/4885SMN1; SMN2 2477/4885LMNA 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.